Results 91 to 100 of about 724,283 (165)

Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data

Health Economics Review
Background Biosimilars are biologic drugs that have the potential to increase the efficiency of healthcare spending and curb drug-related cost increases.
Marko Krstic, Jean-Christophe Devaud, Farshid Sadeghipour, Joachim Marti   +3 more
doaj   +1 more source

No difference in TNF-alfa neutralizing effect comparing IFX with IFX biosimilar CT-P13 (Inflectra).

, 2018
No difference in TNF-alfa neutralizing effect comparing IFX with IFX biosimilar CT-P13 (Inflectra).
B. T. Pham (6069263), G. Dijkstra (6069272), K. N. Faber (6069266), T. Blokzijl (6069257), E. A. M. Festen (6069260), E. Brouwer (6069269), D. J. Buurman (6069254)   +6 more
core   +1 more source

A Comparison of Intravenous Infliximab Versus Subcutaneous Infliximab on Remission Rates, Safety, Costs, Patient Preferences in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Gastro Hep Advances
Background and Aims: Infliximab, widely used as a mainstay treatment of inflammatory bowel disease (IBD), is traditionally administered intravenously. The subcutaneous (SC) formulation appears to offer a more convenient route of administration. This is a
Alejandro Nieto Dominguez, Abhishek Bhurwal, Hemant Mutneja, Sarah E. Eichinger, Bhanu Pinnam, Daniel Guifarro Rivera, Chun-Wei Pan   +6 more
doaj   +1 more source

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability

Drug Design, Development and Therapy, 2017
Andrea Becciolini,1 Maria Gabriella Raimondo,2 Chiara Crotti,2 Elena Agape,2 Martina Biggioggero,2 Ennio Giulio Favalli1 1Department of Rheumatology, 2Department of Clinical Sciences and Health Community, University of Milan, Division of Rheumatology ...
Becciolini A, Raimondo MG, Crotti C, Agape E, Biggioggero M, Favalli EG   +5 more
doaj  

Functional interactions of the Tax and p13 proteins of Human T-cell Leukemia Virus Type I [PDF]

, 2013
Human T-cell leukemia virus type 1 (HTLV-1) establishes a lifelong persistent infection in humans. Approximately 3% of the infected individuals will develop adult T-cell leukemia/lymphoma (ATLL), an aggressive malignancy of mature CD4+ T-cells. The viral
Manicone, Mariangela
core  

Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea

, 2015
OBJECTIVE: To evaluate the safety and efficacy of CT-P13 (Remsima(®)) in patients with inflammatory bowel disease (IBD) in South Korea. METHODS: This post-marketing study included patients with active moderate-to-severe Crohn's disease (CD), fistulizing
천재희
core   +1 more source

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. [PDF]

Drug Saf, 2023
Takeuchi T, Nishikawa K, Yamada F, Morita A, Ohtsuki M, Suzuki Y, Watanabe M, Yamanaka H, Hibi T.   +8 more
europepmc   +1 more source

Biosimilar CT-P13 in treating ulcerative colitis in the real world [PDF]

Minerva Gastroenterology, 2017
Davide G, Ribaldone, Marco, Astegiano
openaire   +3 more sources

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. [PDF]

J Crohns Colitis, 2022
Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S.   +19 more
europepmc   +1 more source

Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis. [PDF]

J Dermatol, 2022
Morita A, Nishikawa K, Yamada F, Yamanaka K, Nakajima H, Ohtsuki M.   +5 more
europepmc   +1 more source